QY-1-T is under clinical development by Zhongke Qiyuan (Shenzhen) Biotechnology and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how QY-1-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QY-1-T overview

QY-1-T is under development for the treatment of HBV-associated advanced hepatocellular carcinoma (HCC). The therapeutic candidate comprises of T-cells genetically engineered to express T cell receptors (TCRs). It is administered through parenteral route.

Zhongke Qiyuan (Shenzhen) Biotechnology overview

Zhongke Qiyuan (Shenzhen) Biotechnology is a biotechnology company engaged in resaerch and development of novel drugs for the treatment of liver cancer. The company is headquartered in Shenzhen, Guangdong, China.

For a complete picture of QY-1-T’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.